We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+9.77%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$203M
AUM Growth
+$18.8M
Cap. Flow
+$773K
Cap. Flow %
0.38%
Top 10 Hldgs %
50.6%
Holding
95
New
11
Increased
22
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
BIDU icon
Baidu
BIDU
+$2.05M
2
AMGN icon
Amgen
AMGN
+$966K
3
TDOC icon
Teladoc Health
TDOC
+$933K
4
GDX icon
VanEck Gold Miners ETF
GDX
+$739K
5
PRTA icon
Prothena Corp
PRTA
+$684K

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.52M
2
XNCR icon
Xencor
XNCR
+$608K
3
IMGN
Immunogen Inc
IMGN
+$415K
4
ORCL icon
Oracle
ORCL
+$372K
5
BUR icon
Burford Capital
BUR
+$263K

Sector Composition

Rank Sector Weight
1 Healthcare 29.96%
2 Technology 19.82%
3 Communication Services 7.67%
4 Consumer Discretionary 3.77%
5 Financials 3.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$21.2M 10.43%
+40,500
New +$20.2M
MU icon
2
Micron Technology
MU
$930B
$18.8M 9.26%
159,500
+4,500
+3% +$407K
GOOG icon
3
Alphabet (Google) Class C
GOOG
$4.36T
$10.9M 5.37%
71,650
+1,500
+2% +$217K
REGN icon
4
Regeneron Pharmaceuticals
REGN
$78.5B
$10.2M 5.02%
10,600
-1,600
-13% -$1.52M
QQQ icon
5
PUT
Invesco QQQ Trust
QQQ
$453B
$8.88M 4.37%
20,000
-35,000
-64% -$15M
ARGX icon
6
argenx
ARGX
$53.4B
$7.95M 3.92%
20,200
-250
-1% -$96.9K
AMD icon
7
Advanced Micro Devices
AMD
$776B
$6.86M 3.38%
38,000
– –
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.7M 3.3%
96,857
– –
ABBV icon
9
AbbVie
ABBV
$443B
$5.79M 2.85%
31,800
-700
-2% -$121K
LLY icon
10
Eli Lilly
LLY
$1.02T
$5.45M 2.68%
7,000
– –
ORCL icon
11
Oracle
ORCL
$374B
$5.12M 2.52%
40,750
-3,250
-7% -$372K
ET icon
12
Energy Transfer Partners
ET
$70.1B
$4.86M 2.4%
309,250
-750
-0.2% -$10.9K
BAC icon
13
Bank of America
BAC
$435B
$4.75M 2.34%
125,350
-3,400
-3% -$117K
XNCR icon
14
Xencor
XNCR
$1.5B
$4.62M 2.28%
208,979
-28,128
-12% -$608K
GLD icon
15
SPDR Gold Trust
GLD
$131B
$4.53M 2.23%
22,000
-1,000
-4% -$192K
IAU icon
16
iShares Gold Trust
IAU
$62.9B
$4.2M 2.07%
100,000
– –
SPYM
17
PUT
State Street SPDR Portfolio S&P 500 ETF
SPYM
$161B
$3.69M 1.82%
60,000
-77,000
-56% -$4.51M
INCY icon
18
Incyte
INCY
$24.2B
$2.93M 1.45%
51,500
+9,000
+21% +$540K
AMGN icon
19
Amgen
AMGN
$208B
$2.93M 1.44%
10,300
+3,300
+47% +$966K
ZBH icon
20
Zimmer Biomet
ZBH
$18.2B
$2.87M 1.41%
21,719
+3,322
+18% +$415K
BABA icon
21
Alibaba
BABA
$293B
$2.77M 1.37%
38,300
+500
+1% +$36.6K
PRTA icon
22
Prothena Corp
PRTA
$425M
$2.65M 1.31%
107,000
+23,000
+27% +$684K
AAPL icon
23
Apple
AAPL
$4.54T
$2.53M 1.25%
14,750
– –
TPB icon
24
Turning Point Brands
TPB
$1.45B
$2.45M 1.21%
83,500
– –
IWM icon
25
iShares Russell 2000 ETF
IWM
$79.8B
$2.42M 1.19%
11,500
– –
1
2 3 4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q1 2024 Portfolio in Review

As of Q1 2024, DCF Advisers held 95 positions worth $203M, up 10% from $184M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DCF Advisers's Q1 2024 filing shows 11 new, 22 increased, 17 reduced and 12 closed positions. Its largest new stake was Baidu: 19,250 shares worth $2.03M. The largest sale was Regeneron Pharmaceuticals, an estimated $1.52M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Technology and Communication Services.

  • DCF Advisers's largest Q1 2024 buy was Baidu: 19,250 shares worth $2.03M.
  • DCF Advisers added most to Amgen in Q1 2024, an estimated $966K increase.
  • DCF Advisers's biggest Q1 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.52M.
  • DCF Advisers fully exited Immunogen Inc in Q1 2024, selling an estimated $415K.
  • DCF Advisers's ten largest holdings make up 51% of its $203M portfolio in Q1 2024.
  • DCF Advisers opened 11 new positions and closed 12 in Q1 2024.
  • DCF Advisers's portfolio value rose 10% quarter-over-quarter to $203M.

Based on DCF Advisers's 13F filing for Q1 2024, filed 15 May 2024.